Anti-SARS-CoV-2 nucleocapsid antibody positivity 3 years after COVID-19
This study aimed to comprehensively assess anti-nucleocapsid antibody positivity using diverse commercial and in-house immunoassays among individuals who contracted COVID-19 more than 3 years ago. We enrolled 44 participants with laboratory-confirmed COVID-19 between January and May 2020 from Seoul National University Hospital and its community treatment centers. The results showed anti-nucleocapsid antibody positivities ranged from 45.5% to 87.9% depending upon the immunoassay used. The study highlights the importance of considering the limited anti-nucleocapsid antibody positivity in participants with a distant COVID-19 history in seroepidemiological or vaccine research.PMID:38684427 | DOI:10.7883/yoken.JJID.2024.011
Source: Japanese Journal of Infectious Diseases - Category: Infectious Diseases Authors: Chang Kyung Kang Youngju Kim Hyeon Jae Jo Chan Mi Lee Nam Joong Kim Chang-Han Lee Pyoeng Gyun Choe Wan Beom Park Myoung-Don Oh Source Type: research
More News: Coronavirus | Covid Vaccine | COVID-19 | Hospitals | Infectious Diseases | Japan Health | Laboratory Medicine | Respiratory Medicine | SARS | Study | Vaccines